207 related articles for article (PubMed ID: 17567143)
21. Promise of bitter melon (Momordica charantia) bioactives in cancer prevention and therapy.
Raina K; Kumar D; Agarwal R
Semin Cancer Biol; 2016 Oct; 40-41():116-129. PubMed ID: 27452666
[TBL] [Abstract][Full Text] [Related]
22. Serum sialic acid changes in non-insulin-dependant diabetes mellitus (NIDDM) patients following bitter melon (Momordica charantia) and rosiglitazone (Avandia) treatment.
Inayat-ur-Rahman ; Malik SA; Bashir M; Khan R; Iqbal M
Phytomedicine; 2009 May; 16(5):401-5. PubMed ID: 19362455
[TBL] [Abstract][Full Text] [Related]
23. Fractionation and identification of 9c, 11t, 13t-conjugated linolenic acid as an activator of PPARalpha in bitter gourd (Momordica charantia L.).
Chuang CY; Hsu C; Chao CY; Wein YS; Kuo YH; Huang CJ
J Biomed Sci; 2006 Nov; 13(6):763-72. PubMed ID: 16955349
[TBL] [Abstract][Full Text] [Related]
24. Debittering of bitter gourd juice using β-cyclodextrin: Mechanism and effect on antidiabetic potential.
Deshaware S; Gupta S; Singhal RS; Joshi M; Variyar PS
Food Chem; 2018 Oct; 262():78-85. PubMed ID: 29751925
[TBL] [Abstract][Full Text] [Related]
25. Bitter melon: a panacea for inflammation and cancer.
Dandawate PR; Subramaniam D; Padhye SB; Anant S
Chin J Nat Med; 2016 Feb; 14(2):81-100. PubMed ID: 26968675
[TBL] [Abstract][Full Text] [Related]
26. Strategies to improve palatability and increase consumption intentions for Momordica charantia (bitter melon): a vegetable commonly used for diabetes management.
Snee LS; Nerurkar VR; Dooley DA; Efird JT; Shovic AC; Nerurkar PV
Nutr J; 2011 Jul; 10():78. PubMed ID: 21794176
[TBL] [Abstract][Full Text] [Related]
27. Thermal treatment enhances the α-glucosidase inhibitory activity of bitter melon (Momordica charantia) by increasing the free form of phenolic compounds and the contents of Maillard reaction products.
Hsieh HJ; Lin JA; Chen KT; Cheng KC; Hsieh CW
J Food Sci; 2021 Jul; 86(7):3109-3121. PubMed ID: 34146408
[TBL] [Abstract][Full Text] [Related]
28. Immunoaffinity purification of α-momorcharin from bitter melon seeds (Momordica charantia).
Yao X; Li J; Deng N; Wang S; Meng Y; Shen F
J Sep Sci; 2011 Nov; 34(21):3092-8. PubMed ID: 21994203
[TBL] [Abstract][Full Text] [Related]
29. Modulatory effect of bitter gourd (Momordica charantia LINN.) on alterations in kidney heparan sulfate in streptozotocin-induced diabetic rats.
Kumar GS; Shetty AK; Salimath PV
J Ethnopharmacol; 2008 Jan; 115(2):276-83. PubMed ID: 18024034
[TBL] [Abstract][Full Text] [Related]
30. Identification of chemotypes in bitter melon by metabolomics: a plant with potential benefit for management of diabetes in traditional Chinese medicine.
Zhou S; Allard PM; Wolfrum C; Ke C; Tang C; Ye Y; Wolfender JL
Metabolomics; 2019 Jul; 15(8):104. PubMed ID: 31321563
[TBL] [Abstract][Full Text] [Related]
31. Momordica charantia (bitter melon). Monograph.
Altern Med Rev; 2007 Dec; 12(4):360-3. PubMed ID: 18069905
[No Abstract] [Full Text] [Related]
32. Quantitative determination of cucurbitane-type triterpenes and triterpene glycosides in dietary supplements containing bitter melon (Momordica charantia) by HPLC-MS/MS.
Ma J; Krynitsky AJ; Grundel E; Rader JI
J AOAC Int; 2012; 95(6):1597-608. PubMed ID: 23451374
[TBL] [Abstract][Full Text] [Related]
33. Cytotoxicity analysis of active components in bitter melon (Momordica charantia) seed extracts using human embryonic kidney and colon tumor cells.
Chipps ES; Jayini R; Ando S; Protzman AD; Muhi MZ; Mottaleb MA; Malkawi A; Islam MR
Nat Prod Commun; 2012 Sep; 7(9):1203-8. PubMed ID: 23074909
[TBL] [Abstract][Full Text] [Related]
34. Accumulation of Charantin and Expression of Triterpenoid Biosynthesis Genes in Bitter Melon (Momordica charantia).
Cuong DM; Jeon J; Morgan AMA; Kim C; Kim JK; Lee SY; Park SU
J Agric Food Chem; 2017 Aug; 65(33):7240-7249. PubMed ID: 28737900
[TBL] [Abstract][Full Text] [Related]
35. Bitter melon (Momordica charantia): a review of efficacy and safety.
Basch E; Gabardi S; Ulbricht C
Am J Health Syst Pharm; 2003 Feb; 60(4):356-9. PubMed ID: 12625217
[TBL] [Abstract][Full Text] [Related]
36. Bitter melon (Momordica charantia L.) inhibits adipocyte hypertrophy and down regulates lipogenic gene expression in adipose tissue of diet-induced obese rats.
Huang HL; Hong YW; Wong YH; Chen YN; Chyuan JH; Huang CJ; Chao PM
Br J Nutr; 2008 Feb; 99(2):230-9. PubMed ID: 17651527
[TBL] [Abstract][Full Text] [Related]
37. Antiulcer activity of methanolic extract of Momordica charantia L. in rats.
Alam S; Asad M; Asdaq SM; Prasad VS
J Ethnopharmacol; 2009 Jun; 123(3):464-9. PubMed ID: 19501279
[TBL] [Abstract][Full Text] [Related]
38. Studies on the antioxygenic activity of bitter gourd (Momordica charantia) and its fractions using various in vitro models.
Padmashree A; Sharma GK; Semwal AD; Bawa AS
J Sci Food Agric; 2011 Mar; 91(4):776-82. PubMed ID: 21302334
[TBL] [Abstract][Full Text] [Related]
39. Characterization of a soluble phosphatidic acid phosphatase in bitter melon (Momordica charantia).
Cao H; Sethumadhavan K; Grimm CC; Ullah AH
PLoS One; 2014; 9(9):e106403. PubMed ID: 25203006
[TBL] [Abstract][Full Text] [Related]
40. Residue analysis and dietary risk assessment of abamectin in fresh corn, bitter melon, and Fritillaria.
Luo X; Zhang C; Luo Y; Fang N; Wang X; He H; Jiang J; Chen Y; Cai Z; Zhao X
Biomed Chromatogr; 2024 Feb; 38(2):e5779. PubMed ID: 38050189
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
